Posted by Michael Wonder on 15 Mar 2022
New access tool launched as part of SMC’s joint work on streamlining patient access to innovative medicines
8 March 2022 - A new UK wide health technology assessment access forum has been developed by partners including the SMC as part of the Innovative Licensing and Access Pathway.
The Innovative Licensing and Access Pathway (ILAP) aims to accelerate the time to market, facilitating patient access to medicines. These medicines include new chemical entities, biological medicines, new indications and repurposed medicines.
SMC is a permanent partner in ILAP, alongside the All Wales Therapeutics and Toxicology Centre, the MHRA and NICE.
